Reported Earnings • May 17
Full year 2026 earnings released: EPS: JP¥31.89 (vs JP¥9.05 in FY 2025) Full year 2026 results: EPS: JP¥31.89 (up from JP¥9.05 in FY 2025). Revenue: JP¥3.36b (up 4.9% from FY 2025). Net income: JP¥141.0m (up 253% from FY 2025). Profit margin: 4.2% (up from 1.2% in FY 2025). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 3% per year but the company’s share price has increased by 10% per year, which means it is well ahead of earnings. Announcement • May 13
atect corporation, Annual General Meeting, Jun 24, 2026 atect corporation, Annual General Meeting, Jun 24, 2026. Valuation Update With 7 Day Price Move • May 13
Investor sentiment improves as stock rises 18% After last week's 18% share price gain to JP¥890, the stock trades at a trailing P/E ratio of 29.8x. Average trailing P/E is 23x in the Life Sciences industry in Japan. Total returns to shareholders of 81% over the past three years. Valuation Update With 7 Day Price Move • Apr 16
Investor sentiment improves as stock rises 17% After last week's 17% share price gain to JP¥817, the stock trades at a trailing P/E ratio of 27.4x. Average trailing P/E is 22x in the Life Sciences industry in Japan. Total returns to shareholders of 47% over the past three years. Upcoming Dividend • Mar 23
Upcoming dividend of JP¥10.00 per share Eligible shareholders must have bought the stock before 30 March 2026. Payment date: 26 June 2026. Payout ratio is a comfortable 33% and this is well supported by cash flows. Trailing yield: 1.5%. Lower than top quartile of Japanese dividend payers (3.6%). Lower than average of industry peers (2.8%). Valuation Update With 7 Day Price Move • Mar 04
Investor sentiment deteriorates as stock falls 20% After last week's 20% share price decline to JP¥741, the stock trades at a trailing P/E ratio of 24.8x. Average trailing P/E is 25x in the Life Sciences industry in Japan. Total returns to shareholders of 38% over the past three years. Reported Earnings • Feb 16
Third quarter 2026 earnings released: EPS: JP¥8.14 (vs JP¥0.45 in 3Q 2025) Third quarter 2026 results: EPS: JP¥8.14 (up from JP¥0.45 in 3Q 2025). Revenue: JP¥876.0m (up 13% from 3Q 2025). Net income: JP¥36.0m (up JP¥34.0m from 3Q 2025). Profit margin: 4.1% (up from 0.3% in 3Q 2025). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 28% per year but the company’s share price has increased by 13% per year, which means it is well ahead of earnings. Valuation Update With 7 Day Price Move • Feb 16
Investor sentiment improves as stock rises 20% After last week's 20% share price gain to JP¥749, the stock trades at a trailing P/E ratio of 33.8x. Average trailing P/E is 24x in the Life Sciences industry in Japan. Total returns to shareholders of 52% over the past three years. New Risk • Jan 28
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Japanese stocks, typically moving 8.1% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (6.1% operating cash flow to total debt). Share price has been highly volatile over the past 3 months (8.1% average weekly change). Earnings have declined by 31% per year over the past 5 years. Minor Risk Market cap is less than US$100m (JP¥3.00b market cap, or US$19.7m). Valuation Update With 7 Day Price Move • Jan 28
Investor sentiment improves as stock rises 18% After last week's 18% share price gain to JP¥684, the stock trades at a trailing P/E ratio of 30.9x. Average trailing P/E is 24x in the Life Sciences industry in Japan. Total returns to shareholders of 34% over the past three years. Announcement • Dec 03
atect corporation to Report Q3, 2026 Results on Feb 13, 2026 atect corporation announced that they will report Q3, 2026 results on Feb 13, 2026 Valuation Update With 7 Day Price Move • Dec 01
Investor sentiment improves as stock rises 16% After last week's 16% share price gain to JP¥510, the stock trades at a trailing P/E ratio of 38.9x. Average trailing P/E is 18x in the Life Sciences industry in Japan. Total returns to shareholders of 6.1% over the past three years. New Risk • Nov 27
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Japanese stocks, typically moving 5.6% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (5.8% operating cash flow to total debt). Earnings have declined by 33% per year over the past 5 years. Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Share price has been volatile over the past 3 months (5.6% average weekly change). Large one-off items impacting financial results. Market cap is less than US$100m (JP¥2.25b market cap, or US$14.4m). Announcement • Nov 05
atect corporation to Report Q2, 2026 Results on Nov 14, 2025 atect corporation announced that they will report Q2, 2026 results on Nov 14, 2025 Reported Earnings • Aug 10
First quarter 2026 earnings released: EPS: JP¥13.12 (vs JP¥9.05 in 1Q 2025) First quarter 2026 results: EPS: JP¥13.12 (up from JP¥9.05 in 1Q 2025). Revenue: JP¥826.0m (down 7.0% from 1Q 2025). Net income: JP¥58.0m (up 45% from 1Q 2025). Profit margin: 7.0% (up from 4.5% in 1Q 2025). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 58 percentage points per year, which is a significant difference in performance. New Risk • Aug 10
New minor risk - Earnings quality The company has large one-off items impacting its financial results. One-off items were 27% of the size of the rest of the company's trailing 12-month earnings before tax. This is considered a minor risk. One-off items are incomes or expenses that the company does not expect to repeat in future periods. Examples include profits from the sale of a business or expenses from a restructuring or legal settlements. If the company's reported statutory earnings include a large proportion of one-off items it means they may be an unreliable indicator of its true business performance as the earnings were skewed by these incomes or expenses. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (5.8% operating cash flow to total debt). Earnings have declined by 33% per year over the past 5 years. Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Large one-off items impacting financial results. Market cap is less than US$100m (JP¥1.86b market cap, or US$12.6m). Announcement • Aug 02
atect corporation to Report Q1, 2026 Results on Aug 08, 2025 atect corporation announced that they will report Q1, 2026 results on Aug 08, 2025 Reported Earnings • May 21
Full year 2025 earnings released: EPS: JP¥9.05 (vs JP¥55.19 loss in FY 2024) Full year 2025 results: EPS: JP¥9.05 (up from JP¥55.19 loss in FY 2024). Revenue: JP¥3.20b (flat on FY 2024). Net income: JP¥40.0m (up JP¥284.0m from FY 2024). Profit margin: 1.2% (up from net loss in FY 2024). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 67 percentage points per year, which is a significant difference in performance. Announcement • May 15
atect corporation, Annual General Meeting, Jun 25, 2025 atect corporation, Annual General Meeting, Jun 25, 2025. Announcement • Mar 27
atect corporation to Report Fiscal Year 2025 Results on May 14, 2025 atect corporation announced that they will report fiscal year 2025 results on May 14, 2025 Upcoming Dividend • Mar 21
Upcoming dividend of JP¥10.00 per share Eligible shareholders must have bought the stock before 28 March 2025. Payment date: 27 June 2025. The company is not currently making a profit and there are not enough cash flows to support it either. Trailing yield: 2.2%. Lower than top quartile of Japanese dividend payers (3.7%). Lower than average of industry peers (2.8%). New Risk • Feb 27
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Japanese stocks, typically moving 8.3% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (1.1x net interest cover). Share price has been highly volatile over the past 3 months (8.3% average weekly change). Dividend is not well covered by earnings and cash flows. Paying a dividend despite being loss-making. Cash payout ratio: 158% Earnings have declined by 36% per year over the past 5 years. Minor Risk Market cap is less than US$100m (JP¥2.26b market cap, or US$15.1m). Reported Earnings • Feb 08
Third quarter 2025 earnings released: EPS: JP¥0.45 (vs JP¥3.85 loss in 3Q 2024) Third quarter 2025 results: EPS: JP¥0.45 (up from JP¥3.85 loss in 3Q 2024). Revenue: JP¥773.0m (up 2.9% from 3Q 2024). Net income: JP¥2.00m (up JP¥19.0m from 3Q 2024). Profit margin: 0.3% (up from net loss in 3Q 2024). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 74 percentage points per year, which is a significant difference in performance. Announcement • Jan 17
atect corporation to Report Q3, 2025 Results on Feb 07, 2025 atect corporation announced that they will report Q3, 2025 results on Feb 07, 2025 New Risk • Jan 09
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Japanese stocks, typically moving 5.2% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (4.1% operating cash flow to total debt). Dividend is not well covered by earnings and cash flows. Paying a dividend despite being loss-making. Cash payout ratio: 158% Earnings have declined by 26% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (5.2% average weekly change). Market cap is less than US$100m (JP¥1.88b market cap, or US$11.9m). New Risk • Dec 25
New major risk - Market cap size The company's market capitalization is less than US$10m. Market cap: JP¥1.57b (US$9.99m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (4.1% operating cash flow to total debt). Dividend is not well covered by earnings and cash flows. Paying a dividend despite being loss-making. Cash payout ratio: 158% Earnings have declined by 26% per year over the past 5 years. Market cap is less than US$10m (JP¥1.57b market cap, or US$9.99m). Reported Earnings • Nov 11
Second quarter 2025 earnings released: JP¥3.62 loss per share (vs JP¥6.33 profit in 2Q 2024) Second quarter 2025 results: JP¥3.62 loss per share (down from JP¥6.33 profit in 2Q 2024). Revenue: JP¥764.0m (down 8.5% from 2Q 2024). Net loss: JP¥16.0m (down 157% from profit in 2Q 2024). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 59 percentage points per year, which is a significant difference in performance. Buy Or Sell Opportunity • Nov 11
Now 24% undervalued after recent price drop Over the last 90 days, the stock has fallen 16% to JP¥464. The fair value is estimated to be JP¥614, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has been flat over the last 3 years. Meanwhile, the company became loss making. Announcement • Oct 11
atect corporation to Report Q2, 2025 Results on Nov 08, 2024 atect corporation announced that they will report Q2, 2025 results on Nov 08, 2024 New Risk • Sep 17
New major risk - Financial data availability The company has not reported any financial data. This is considered a major risk. With no or incomplete audited reported financial data, it is virtually impossible to assess the company's investment potential. Currently, the following risks have been identified for the company: Major Risk No financial data reported. Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Market cap is less than US$100m (JP¥2.26b market cap, or US$16.1m). Announcement • Jul 17
atect corporation to Report Q1, 2025 Results on Aug 07, 2024 atect corporation announced that they will report Q1, 2025 results on Aug 07, 2024 New Risk • May 17
New major risk - Financial position The company's debt is not well covered by operating cash flow. Operating cash flow to total debt ratio: 19% This is considered a major risk. If the company's operating cash flows are too small relative to the size of their debt, it increases their balance sheet risk. The company has less cash from operations to cover its expenses from servicing large debt and it increases the risk of liquidity issues. It also extends the time it would take for the company to pay back the debt in full, meaning it may not be able to easily pay it all off in a distress scenario. Currently, the following risks have been identified for the company: Major Risk Debt is not well covered by operating cash flow (19% operating cash flow to total debt). Minor Risks Share price has been volatile over the past 3 months (6.2% average weekly change). Market cap is less than US$100m (JP¥3.19b market cap, or US$20.5m). Reported Earnings • May 13
Full year 2024 earnings released: JP¥55.19 loss per share (vs JP¥35.74 profit in FY 2023) Full year 2024 results: JP¥55.19 loss per share (down from JP¥35.74 profit in FY 2023). Revenue: JP¥3.18b (up 7.2% from FY 2023). Net loss: JP¥244.0m (down 254% from profit in FY 2023). Over the last 3 years on average, earnings per share has fallen by 29% per year but the company’s share price has only fallen by 7% per year, which means it has not declined as severely as earnings. Announcement • May 12
atect corporation, Annual General Meeting, Jun 26, 2024 atect corporation, Annual General Meeting, Jun 26, 2024. Buy Or Sell Opportunity • Apr 12
Now 21% undervalued after recent price drop Over the last 90 days, the stock has fallen 32% to JP¥790. The fair value is estimated to be JP¥1,004, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has been flat over the last 3 years. Meanwhile, the company has become profitable. Announcement • Mar 28
atect corporation to Report Fiscal Year 2024 Results on May 10, 2024 atect corporation announced that they will report fiscal year 2024 results on May 10, 2024 Buy Or Sell Opportunity • Mar 26
Now 21% undervalued Over the last 90 days, the stock has risen 12% to JP¥789. The fair value is estimated to be JP¥1,005, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has been flat over the last 3 years. Meanwhile, the company has become profitable. Upcoming Dividend • Mar 21
Upcoming dividend of JP¥10.00 per share Eligible shareholders must have bought the stock before 28 March 2024. Payment date: 24 June 2024. Payout ratio is a comfortable 39% and this is well supported by cash flows. Trailing yield: 1.2%. Lower than top quartile of Japanese dividend payers (3.2%). Lower than average of industry peers (2.3%). Buy Or Sell Opportunity • Mar 11
Now 22% undervalued Over the last 90 days, the stock has risen 12% to JP¥792. The fair value is estimated to be JP¥1,017, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has been flat over the last 3 years. Meanwhile, the company has become profitable. Valuation Update With 7 Day Price Move • Feb 14
Investor sentiment deteriorates as stock falls 17% After last week's 17% share price decline to JP¥870, the stock trades at a trailing P/E ratio of 34x. Average trailing P/E is 14x in the Life Sciences industry in Japan. Total loss to shareholders of 3.8% over the past three years. Reported Earnings • Feb 09
Third quarter 2024 earnings released: JP¥3.85 loss per share (vs JP¥7.69 profit in 3Q 2023) Third quarter 2024 results: JP¥3.85 loss per share (down from JP¥7.69 profit in 3Q 2023). Revenue: JP¥751.0m (down 2.5% from 3Q 2023). Net loss: JP¥17.0m (down 150% from profit in 3Q 2023). Over the last 3 years on average, earnings per share has increased by 20% per year but the company’s share price has fallen by 5% per year, which means it is significantly lagging earnings. Valuation Update With 7 Day Price Move • Jan 26
Investor sentiment deteriorates as stock falls 15% After last week's 15% share price decline to JP¥1,080, the stock trades at a trailing P/E ratio of 29.1x. Average trailing P/E is 15x in the Life Sciences industry in Japan. Total returns to shareholders of 15% over the past three years. Announcement • Jan 11
atect corporation to Report Q3, 2024 Results on Feb 07, 2024 atect corporation announced that they will report Q3, 2024 results on Feb 07, 2024 Valuation Update With 7 Day Price Move • Dec 28
Investor sentiment improves as stock rises 15% After last week's 15% share price gain to JP¥782, the stock trades at a trailing P/E ratio of 21.1x. Average trailing P/E is 15x in the Life Sciences industry in Japan. Total loss to shareholders of 7.8% over the past three years. Valuation Update With 7 Day Price Move • Nov 30
Investor sentiment improves as stock rises 22% After last week's 22% share price gain to JP¥801, the stock trades at a trailing P/E ratio of 21.6x. Average trailing P/E is 15x in the Life Sciences industry in Japan. Total loss to shareholders of 20% over the past three years. Reported Earnings • Nov 11
Second quarter 2024 earnings released: EPS: JP¥6.33 (vs JP¥9.95 in 2Q 2023) Second quarter 2024 results: EPS: JP¥6.33 (down from JP¥9.95 in 2Q 2023). Revenue: JP¥835.0m (up 21% from 2Q 2023). Net income: JP¥28.0m (down 36% from 2Q 2023). Profit margin: 3.4% (down from 6.4% in 2Q 2023). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 36% per year but the company’s share price has fallen by 13% per year, which means it is significantly lagging earnings. Valuation Update With 7 Day Price Move • Nov 09
Investor sentiment deteriorates as stock falls 17% After last week's 17% share price decline to JP¥603, the stock trades at a trailing P/E ratio of 14.8x. Average trailing P/E is 15x in the Life Sciences industry in Japan. Total loss to shareholders of 30% over the past three years. Announcement • Sep 28
atect corporation to Report Q2, 2024 Results on Nov 08, 2023 atect corporation announced that they will report Q2, 2024 results on Nov 08, 2023 Valuation Update With 7 Day Price Move • Aug 22
Investor sentiment improves as stock rises 16% After last week's 16% share price gain to JP¥739, the stock trades at a trailing P/E ratio of 18.2x. Average trailing P/E is 16x in the Life Sciences industry in Japan. Total loss to shareholders of 11% over the past three years. Reported Earnings • Aug 09
First quarter 2024 earnings released: EPS: JP¥17.19 (vs JP¥12.22 in 1Q 2023) First quarter 2024 results: EPS: JP¥17.19 (up from JP¥12.22 in 1Q 2023). Revenue: JP¥864.0m (up 15% from 1Q 2023). Net income: JP¥76.0m (up 41% from 1Q 2023). Profit margin: 8.8% (up from 7.2% in 1Q 2023). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 48% per year but the company’s share price has fallen by 6% per year, which means it is significantly lagging earnings. New Risk • Aug 08
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Japanese stocks, typically moving 8.5% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (13% operating cash flow to total debt). Share price has been highly volatile over the past 3 months (8.5% average weekly change). Minor Risk Market cap is less than US$100m (JP¥2.91b market cap, or US$20.5m). Valuation Update With 7 Day Price Move • Aug 07
Investor sentiment improves as stock rises 23% After last week's 23% share price gain to JP¥659, the stock trades at a trailing P/E ratio of 18.4x. Average trailing P/E is 18x in the Life Sciences industry in Japan. Total loss to shareholders of 21% over the past three years. Announcement • Jun 28
atect corporation to Report Q1, 2024 Results on Aug 04, 2023 atect corporation announced that they will report Q1, 2024 results on Aug 04, 2023 Reported Earnings • Jun 28
Full year 2023 earnings released: EPS: JP¥35.74 (vs JP¥38.26 in FY 2022) Full year 2023 results: EPS: JP¥35.74 (down from JP¥38.26 in FY 2022). Revenue: JP¥2.96b (down 4.1% from FY 2022). Net income: JP¥158.0m (down 6.5% from FY 2022). Profit margin: 5.3% (down from 5.5% in FY 2022). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has increased by 54% per year but the company’s share price has fallen by 11% per year, which means it is significantly lagging earnings. Valuation Update With 7 Day Price Move • Jun 01
Investor sentiment improves as stock rises 26% After last week's 26% share price gain to JP¥653, the stock trades at a trailing P/E ratio of 18.3x. Average trailing P/E is 17x in the Life Sciences industry in Japan. Total loss to shareholders of 25% over the past three years. Announcement • May 12
atect corporation, Annual General Meeting, Jun 21, 2023 atect corporation, Annual General Meeting, Jun 21, 2023. Reported Earnings • May 12
Full year 2023 earnings released: EPS: JP¥35.74 (vs JP¥38.26 in FY 2022) Full year 2023 results: EPS: JP¥35.74 (down from JP¥38.26 in FY 2022). Revenue: JP¥2.96b (down 4.1% from FY 2022). Net income: JP¥158.0m (down 6.5% from FY 2022). Profit margin: 5.3% (down from 5.5% in FY 2022). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has increased by 54% per year but the company’s share price has fallen by 12% per year, which means it is significantly lagging earnings. Upcoming Dividend • Mar 23
Upcoming dividend of JP¥10.00 per share at 1.8% yield Eligible shareholders must have bought the stock before 30 March 2023. Payment date: 23 June 2023. Payout ratio is a comfortable 30% and this is well supported by cash flows. Trailing yield: 1.8%. Lower than top quartile of Japanese dividend payers (3.6%). Higher than average of industry peers (1.6%). Reported Earnings • Feb 04
Third quarter 2023 earnings released: EPS: JP¥7.69 (vs JP¥9.73 in 3Q 2022) Third quarter 2023 results: EPS: JP¥7.69 (down from JP¥9.73 in 3Q 2022). Revenue: JP¥770.0m (up 5.0% from 3Q 2022). Net income: JP¥34.0m (down 21% from 3Q 2022). Profit margin: 4.4% (down from 5.9% in 3Q 2022). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 53% per year but the company’s share price has fallen by 27% per year, which means it is significantly lagging earnings. Announcement • Jan 07
atect corporation to Report Q3, 2023 Results on Feb 03, 2023 atect corporation announced that they will report Q3, 2023 results on Feb 03, 2023 Board Change • Nov 16
Less than half of directors are independent Following the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 2 non-independent directors. Executive Chairman Norio Kotaka was the last director to join the board, commencing their role in 2021. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Reported Earnings • Nov 06
Second quarter 2023 earnings released: EPS: JP¥9.95 (vs JP¥8.37 in 2Q 2022) Second quarter 2023 results: EPS: JP¥9.95 (up from JP¥8.37 in 2Q 2022). Revenue: JP¥690.0m (down 12% from 2Q 2022). Net income: JP¥44.0m (up 19% from 2Q 2022). Profit margin: 6.4% (up from 4.7% in 2Q 2022). Over the last 3 years on average, earnings per share has increased by 48% per year but the company’s share price has fallen by 27% per year, which means it is significantly lagging earnings. Announcement • Aug 31
atect corporation to Report Q2, 2023 Results on Nov 04, 2022 atect corporation announced that they will report Q2, 2023 results on Nov 04, 2022 Reported Earnings • Aug 07
First quarter 2023 earnings released: EPS: JP¥12.22 (vs JP¥16.78 in 1Q 2022) First quarter 2023 results: EPS: JP¥12.22 (down from JP¥16.78 in 1Q 2022). Revenue: JP¥752.0m (down 9.7% from 1Q 2022). Net income: JP¥54.0m (down 27% from 1Q 2022). Profit margin: 7.2% (down from 8.9% in 1Q 2022). Over the last 3 years on average, earnings per share has increased by 36% per year but the company’s share price has fallen by 14% per year, which means it is significantly lagging earnings. Announcement • Jun 29
atect corporation to Report Q1, 2023 Results on Aug 05, 2022 atect corporation announced that they will report Q1, 2023 results on Aug 05, 2022 Reported Earnings • May 13
Full year 2022 earnings released: EPS: JP¥38.26 (vs JP¥17.04 in FY 2021) Full year 2022 results: EPS: JP¥38.26 (up from JP¥17.04 in FY 2021). Revenue: JP¥3.09b (up 8.1% from FY 2021). Net income: JP¥169.0m (up 125% from FY 2021). Profit margin: 5.5% (up from 2.6% in FY 2021). Over the last 3 years on average, earnings per share has increased by 23% per year but the company’s share price has fallen by 14% per year, which means it is significantly lagging earnings. Board Change • Apr 27
No independent directors Following the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 3 non-independent directors. Executive Chairman Tokuo Kodaka was the last director to join the board, commencing their role in 2021. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model. Announcement • Apr 08
atect corporation to Report Fiscal Year 2022 Results on May 11, 2022 atect corporation announced that they will report fiscal year 2022 results on May 11, 2022 Upcoming Dividend • Mar 23
Upcoming dividend of JP¥10.00 per share Eligible shareholders must have bought the stock before 30 March 2022. Payment date: 23 June 2022. Payout ratio is a comfortable 12% and this is well supported by cash flows. Trailing yield: 1.3%. Lower than top quartile of Japanese dividend payers (3.4%). Lower than average of industry peers (2.3%). Valuation Update With 7 Day Price Move • Mar 09
Investor sentiment deteriorated over the past week After last week's 17% share price decline to JP¥638, the stock trades at a trailing P/E ratio of 15.8x. Average trailing P/E is 18x in the Life Sciences industry in Japan. Total loss to shareholders of 42% over the past three years. Reported Earnings • Feb 07
Third quarter 2022 earnings: Revenues and EPS in line with analyst expectations Third quarter 2022 results: EPS: JP¥9.73 (up from JP¥2.73 in 3Q 2021). Revenue: JP¥733.0m (flat on 3Q 2021). Net income: JP¥43.0m (up 258% from 3Q 2021). Profit margin: 5.9% (up from 1.6% in 3Q 2021). Revenue was in line with analyst estimates. Over the last 3 years on average, earnings per share has increased by 2% per year but the company’s share price has fallen by 13% per year, which means it is significantly lagging earnings. Reported Earnings • Nov 07
Second quarter 2022 earnings released: EPS JP¥8.37 (vs JP¥6.82 in 2Q 2021) The company reported a strong second quarter result with improved earnings, revenues and profit margins. Second quarter 2022 results: Revenue: JP¥788.0m (up 14% from 2Q 2021). Net income: JP¥37.0m (up 23% from 2Q 2021). Profit margin: 4.7% (up from 4.4% in 2Q 2021). Over the last 3 years on average, earnings per share has fallen by 19% per year whereas the company’s share price has fallen by 14% per year. Reported Earnings • Aug 12
First quarter 2022 earnings released: EPS JP¥16.78 (vs JP¥1.82 in 1Q 2021) The company reported a strong first quarter result with improved earnings, revenues and profit margins. First quarter 2022 results: Revenue: JP¥833.0m (up 26% from 1Q 2021). Net income: JP¥74.0m (up JP¥66.0m from 1Q 2021). Profit margin: 8.9% (up from 1.2% in 1Q 2021). Over the last 3 years on average, earnings per share has fallen by 34% per year but the company’s share price has only fallen by 7% per year, which means it has not declined as severely as earnings. Reported Earnings • Jun 27
Full year 2021 earnings released: EPS JP¥17.04 (vs JP¥8.67 in FY 2020) The company reported a decent full year result with improved earnings and profit margins, although revenues were weaker. Full year 2021 results: Revenue: JP¥2.86b (down 4.1% from FY 2020). Net income: JP¥75.0m (up 97% from FY 2020). Profit margin: 2.6% (up from 1.3% in FY 2020). Over the last 3 years on average, earnings per share has fallen by 46% per year but the company’s share price has only fallen by 6% per year, which means it has not declined as severely as earnings. Reported Earnings • May 16
Full year 2021 earnings released: EPS JP¥17.04 (vs JP¥8.67 in FY 2020) The company reported a decent full year result with improved earnings and profit margins, although revenues were weaker. Full year 2021 results: Revenue: JP¥2.86b (down 4.1% from FY 2020). Net income: JP¥75.0m (up 97% from FY 2020). Profit margin: 2.6% (up from 1.3% in FY 2020). Over the last 3 years on average, earnings per share has fallen by 46% per year but the company’s share price has only fallen by 12% per year, which means it has not declined as severely as earnings. Upcoming Dividend • Mar 23
Upcoming dividend of JP¥5.00 per share Eligible shareholders must have bought the stock before 30 March 2021. Payment date: 24 June 2021. Trailing yield: 0.3%. Lower than top quartile of Japanese dividend payers (2.7%). Lower than average of industry peers (1.4%). Reported Earnings • Feb 07
Third quarter 2021 earnings released: EPS JP¥2.73 (vs JP¥6.16 in 3Q 2020) The company reported a soft third quarter result with weaker earnings and profit margins, although revenues improved. Third quarter 2021 results: Revenue: JP¥740.0m (up 1.4% from 3Q 2020). Net income: JP¥12.0m (down 56% from 3Q 2020). Profit margin: 1.6% (down from 3.7% in 3Q 2020). Over the last 3 years on average, earnings per share has fallen by 42% per year but the company’s share price has only fallen by 12% per year, which means it has not declined as severely as earnings. Is New 90 Day High Low • Dec 23
New 90-day low: JP¥852 The company is down 5.0% from its price of JP¥893 on 24 September 2020. The Japanese market is up 7.0% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Life Sciences industry, which is down 19% over the same period. Reported Earnings • Nov 09
Second quarter 2021 earnings released: EPS JP¥6.82 The company reported a soft second quarter result with weaker earnings and revenues, although profit margins were improved. Second quarter 2021 results: Revenue: JP¥689.0m (down 12% from 2Q 2020). Net income: JP¥30.0m (down 3.2% from 2Q 2020). Profit margin: 4.4% (up from 4.0% in 2Q 2020). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has fallen by 22% per year whereas the company’s share price has fallen by 18% per year.